Access cutting-edge retinitis pigmentosa treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Access retinitis pigmentosa specialists in Boston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related retinitis pigmentosa treatment provided free
The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.
Sponsor: Laboratoires Thea
Check if you qualify for this retinitis pigmentosa clinical trial in Boston, MA
If you're searching for retinitis pigmentosa treatment options in Boston, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced retinitis pigmentosa specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.